ATOSSA THERAPEUTICS, INC. — Director's Dealing 2019

May 22, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2019-05-17

Reporting Person: Remmel H. Lawrence (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-17	Stock Option (right to buy)	$2.52	A	45000	Acquired	2029-05-17	Common Stock (45000)	Direct

Footnotes

F1: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:00 a.m. (ET) on May 17, 2019 with an exercise price of $2.52, representing the most recently reported closing stock price at the time of grant.